Sasapyrine

• CAT Number: A000715
• CAS Number: 552-94-3
• Molecular Formula: C14H10O5
• Molecular Weight: 258.2
• Purity: ≥95%
• Storage: -20°C
• InChI: InChI=1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17)
• InChIKey: WVYADZUPLLSGPU-UHFFFAOYSA-N
• SMILES: OC1=CC=CC=C1C(OC2=C(C(O)=O)C=CC=C2)=O

Salsalate is a nonsteroidal anti-inflammatory drug, a nonacetylated salicylate with no more problems of gastrointestinal bleeding than placebo. It inhibits synthesis and release of prostaglandins through the inactivation of cyclooxygenase-1 and COX-2. Salsalate is currently being investigated as a treatment for Type 2 diabetes with possible use to prevent the disease in people at risk. It reduces blood glucose concentrations in patients with type 2 diabetes, as well as in insulin-resistant patients without diabetes.

Reference

1: Liang W, Verschuren L, Mulder P, van der Hoorn JW, Verheij J, van Dam AD, Boon MR, Princen HM, Havekes LM, Kleemann R, van den Hoek AM. Salsalate attenuates diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes. Br J Pharmacol. 2015 Nov;172(22):5293-305. doi: 10.1111/bph.13315. Epub 2015 Oct 22. PubMed PMID: 26292849.2: Rubin MR, Goldfine AB, McMahon DJ, Donovan DS, Cremers S, Dworakowski E, Schaefer EJ, Shoelson SE, Silverberg SJ. Effects of the anti-inflammatory drug salsalate on bone turnover in type 2 diabetes mellitus. Endocrine. 2015 Nov;50(2):504-7. doi: 10.1007/s12020-015-0535-8. Epub 2015 Feb 1. PubMed PMID: 25636441; PubMed Central PMCID: PMC4522229.3: Ariel D, Kim SH, Liu A, Abbasi F, Lamendola CA, Grove K, Tomasso V, Reaven GM. Salsalate-induced changes in lipid, lipoprotein, and apoprotein concentrations in overweight or obese, insulin-resistant, nondiabetic individuals. J Clin Lipidol. 2015 Sep-Oct;9(5):658-63. doi: 10.1016/j.jacl.2015.06.009. Epub 2015 Jun 18. PubMed PMID: 26350812; PubMed Central PMCID: PMC4594205.4: Penesova A, Koska J, Ortega E, Bunt JC, Bogardus C, de Courten B. Salsalate has no effect on insulin secretion but decreases insulin clearance: a randomized, placebo-controlled trial in subjects without diabetes. Diabetes Obes Metab. 2015 Jun;17(6):608-12. doi: 10.1111/dom.12450. Epub 2015 Mar 12. PubMed PMID: 25683256.5: van Dam AD, Nahon KJ, Kooijman S, van den Berg SM, Kanhai AA, Kikuchi T, Heemskerk MM, van Harmelen V, Lombès M, van den Hoek AM, de Winther MP, Lutgens E, Guigas B, Rensen PC, Boon MR. Salsalate activates brown adipose tissue in mice. Diabetes. 2015 May;64(5):1544-54. doi: 10.2337/db14-1125. Epub 2014 Dec 4. PubMed PMID: 25475439.6: Alderete TL, Sattler FR, Richey JM, Allayee H, Mittelman SD, Sheng X, Tucci J, Gyllenhammer LE, Grant EG, Goran MI. Salsalate treatment improves glycemia without altering adipose tissue in nondiabetic obese hispanics. Obesity (Silver Spring). 2015 Mar;23(3):543-51. doi: 10.1002/oby.20991. Epub 2015 Feb 3. PubMed PMID: 25644856; PubMed Central PMCID: PMC4340767.7: Kim SH, Liu A, Ariel D, Abbasi F, Lamendola C, Grove K, Tomasso V, Ochoa H, Reaven G. Effect of salsalate on insulin action, secretion, and clearance in nondiabetic, insulin-resistant individuals: a randomized, placebo-controlled study. Diabetes Care. 2014 Jul;37(7):1944-50. doi: 10.2337/dc13-2977. PubMed PMID: 24963111; PubMed Central PMCID: PMC4067392.8: Goldfine AB, Jablonski KA, Shoelson SE, Creager MA; TINSAL-FMD (Targeting Inflammation Using Salsalate in Type 2 Diabetes–Flow-Mediated Dilation) Ancillary Study Team. Response to comment on Goldfine et al. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabetes care 2013;36:4132-4139. Diabetes Care. 2014 May;37(5):e112. doi: 10.2337/dc14-0222. PubMed PMID: 24757239.9: Anderson K, Wherle L, Park M, Nelson K, Nguyen L. Salsalate, an old, inexpensive drug with potential new indications: a review of the evidence from 3 recent studies. Am Health Drug Benefits. 2014 Jun;7(4):231-5. Review. PubMed PMID: 25126374; PubMed Central PMCID: PMC4105730.10: Barzilay JI, Jablonski KA, Fonseca V, Shoelson SE, Goldfine AB, Strauch C, Monnier VM; TINSAL-T2D Research Consortium. The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes. Diabetes Care. 2014 Apr;37(4):1083-91. doi: 10.2337/dc13-1527. Epub 2013 Nov 19. PubMed PMID: 24255104; PubMed Central PMCID: PMC3964486.11: Pierce GL, Siefers K, Wegman-Points L. Comment on Goldfine et al. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabetes care 2013;36:4132-4139. Diabetes Care. 2014 May;37(5):e110-1. doi: 10.2337/dc13-2781. PubMed PMID: 24757238.12: Fakhri M, Imani EF, Khalili N. The effect of salsalate on biochemical factors and endothelial dysfunction of prediabetic patients: A randomized clinical trial. J Res Med Sci. 2014 Apr;19(4):287-92. PubMed PMID: 25097598; PubMed Central PMCID: PMC4115341.13: Wang X, DuBois DC, Cao Y, Jusko WJ, Almon RR. Diabetes disease progression in Goto-Kakizaki rats: effects of salsalate treatment. Diabetes Metab Syndr Obes. 2014 Aug 1;7:381-9. doi: 10.2147/DMSO.S65818. eCollection 2014. PubMed PMID: 25120374; PubMed Central PMCID: PMC4128793.14: Nohria A, Kinlay S, Buck JS, Redline W, Copeland-Halperin R, Kim S, Beckman JA. The effect of salsalate therapy on endothelial function in a broad range of subjects. J Am Heart Assoc. 2014 Jan 3;3(1):e000609. doi: 10.1161/JAHA.113.000609. PubMed PMID: 24390146; PubMed Central PMCID: PMC3959688.15: Goldfine AB, Buck JS, Desouza C, Fonseca V, Chen YD, Shoelson SE, Jablonski KA, Creager MA; TINSAL-FMD (Targeting Inflammation Using Salsalate in Type 2 Diabetes–Flow-Mediated Dilation) Ancillary Study Team. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabetes Care. 2013 Dec;36(12):4132-9. doi: 10.2337/dc13-0859. Epub 2013 Oct 15. PubMed PMID: 24130358; PubMed Central PMCID: PMC3836144.16: Jung TW, Youn BS, Choi HY, Lee SY, Hong HC, Yang SJ, Yoo HJ, Kim BH, Baik SH, Choi KM. Salsalate and adiponectin ameliorate hepatic steatosis by inhibition of the hepatokine fetuin-A. Biochem Pharmacol. 2013 Oct 1;86(7):960-9. doi: 10.1016/j.bcp.2013.07.034. Epub 2013 Aug 13. PubMed PMID: 23948064.17: Faghihimani E, Aminorroaya A, Rezvanian H, Adibi P, Ismail-Beigi F, Amini M. Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes. Acta Diabetol. 2013 Aug;50(4):537-43. doi: 10.1007/s00592-011-0329-2. Epub 2011 Sep 22. PubMed PMID: 21938543.18: Summaries for patients. Salsalate for type 2 diabetes mellitus. Ann Intern Med. 2013 Jul 2;159(1):I-32. doi: 10.7326/0003-4819-159-1-201307020-00001. PubMed PMID: 23817718.19: Goldfine AB, Fonseca V, Jablonski KA, Chen YD, Tipton L, Staten MA, Shoelson SE; Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2013 Jul 2;159(1):1-12. doi: 10.7326/0003-4819-159-1-201307020-00003. PubMed PMID: 23817699; PubMed Central PMCID: PMC4128629.20: Jung TW, Choi HY, Lee SY, Hong HC, Yang SJ, Yoo HJ, Youn BS, Baik SH, Choi KM. Salsalate and Adiponectin Improve Palmitate-Induced Insulin Resistance via Inhibition of Selenoprotein P through the AMPK-FOXO1α Pathway. PLoS One. 2013 Jun 18;8(6):e66529. Print 2013. PubMed PMID: 23825542; PubMed Central PMCID: PMC3689003.